Analytical Data
-
基因名
SUCLG2
- Application
-
别名
SUCLG2；Succinate--CoA ligase [GDP-forming] subunit beta. mitochondrial
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q96I99
-
表达区间
49-423aa
-
氨基酸序列
MSDNGVRVQRFFVADTANEALEAAKRLNAKEIVLKAQILAGGRGKGVFNSGLKGGVHLTKDPNVVGQLAKQMIGYNLATKQTPKEGVKVNKVMVAEALDISRETYLAILMDRSCNGPVLVGSPQGGVDIEEVAASNPELIFKEQIDIFEGIKDSQAQRMAENLGFVGPLKSQAADQITKLYNLFLKIDATQVEVNPFGETPEGQVVCFDAKINFDDNAEFRQKDIFAMDDKSENEPIENEAAKYDLKYIGLDGNIACFVNGAGLAMATCDIIFLNGGKPANFLDLGGGVKEAQVYQAFKLLTADPKVEAILVNIFGGIVNCAIIANGITKACRELELKVPLVVRLEGTNVQEAQKILNNSGLPITSAIDLEDAAK
-
分子量
56.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Identification
Protein Description
SUCLG2 (Succinate-CoA ligase, GDP-forming beta subunit) is a mitochondrial enzyme crucial for energy metabolism, specifically in the context of succinate utilization. As a part of the succinate-CoA ligase complex, SUCLG2 plays an integral role in the citric acid cycle, facilitating the conversion of succinate to succinyl-CoA while generating GTP from GDP. Alterations in the function or expression of SUCLG2 have been linked to various metabolic disorders and certain types of cancer, highlighting its potential as a therapeutic target. Research into the structural and functional properties of SUCLG2, including the development of recombinant protein, is essential for understanding its role in mitochondrial metabolism and energy homeostasis. Through techniques such as site-directed mutagenesis and protein crystallization, scientists aim to elucidate the molecular mechanisms governing its activity. This foundational knowledge could pave the way for the design of novel interventions to modulate SUCLG2’s function in disease contexts, emphasizing its importance in bioenergetics and metabolic regulation. Furthermore, the production of recombinant SUCLG2 offers opportunities for high-throughput screening of small molecules that could enhance or inhibit its activity, thus providing a valuable platform for drug discovery and the development of metabolic therapies.
